Enlivex Therapeutics Files 6-K with Financials
Ticker: ENLV · Form: 6-K · Filed: May 30, 2025 · CIK: 1596812
Sentiment: neutral
Topics: financials, 6-K, foreign-private-issuer
TL;DR
Enlivex dropped its Q1 2025 financials in a 6-K filing.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on May 30, 2025, reporting its unaudited condensed consolidated financial statements for the three-month periods ended March 31, 2025, and March 31, 2024. The filing also includes information about the company's principal executive offices in Nes Ziona, Israel, and its former names, Bioblast Pharma Ltd. and BIO BLAST PHARMA LTD.
Why It Matters
This filing provides investors with the latest financial performance data for Enlivex Therapeutics, crucial for understanding the company's current financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant risk disclosures.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Filer
- Bioblast Pharma Ltd. (company) — Former company name
- BIO BLAST PHARMA LTD. (company) — Former company name
- March 31, 2025 (date) — Reporting period end date
- March 31, 2024 (date) — Reporting period end date
FAQ
What period do the unaudited condensed consolidated financial statements in the 6-K cover?
The unaudited condensed consolidated financial statements cover the three-month periods ended March 31, 2025, and March 31, 2024.
What is the principal executive office address for Enlivex Therapeutics Ltd.?
The principal executive office is located at 14 Einstein Street, Nes Ziona, Israel, 7403618.
What is the SEC file number for Enlivex Therapeutics Ltd.?
The SEC file number is 001-36578.
Has Enlivex Therapeutics Ltd. previously operated under other names?
Yes, the company was formerly known as Bioblast Pharma Ltd. and BIO BLAST PHARMA LTD.
What type of report is this filing?
This filing is a Form 6-K, Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 30, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).